Prevention of osteoporosis: Four-year follow-up of a cohort of postmenopausal women treated with an ossein-hydroxyapatite compound

Clinical Drug Investigation

Volumn 27, Issue 4, 2007, Pages 227-232

  Fernández Pareja, Antonio ^a,e   Hernández Blanco, Elena ^b   Pérez Maceda, José Manuel ^a   Rubio, Vicente José Riera ^a   Palazuelos, Javier Haya ^c   Dalmau, José Manasanch ^d  

^a Centro de Salud Mental Usera   (Spain)

^b SERMAS   (Spain)

^c HOSPITAL UNIVERSITARIO SANTA CRISTINA   (Spain)

^d Centre d'Immunologie Pierre Fabre   (France)

^e NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; HYDROXYAPATITE; OSSEIN HYDROXYAPATITE; OSTEOPOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BONE DENSITY; CONSTIPATION; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFICACY; FEMALE; FOLLOW UP; HEARTBURN; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; NUTRITIONAL ASSESSMENT; OSTEOPENIA; PATIENT COMPLIANCE; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIMARY MEDICAL CARE; PRIORITY JOURNAL;

BONE DENSITY; COHORT STUDIES; DURAPATITE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; OSTEOPOROSIS; POSTMENOPAUSE;

EID: 33947305753     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200727040-00001     Document Type: Article

References (25)

1. Maggi S, Noale M, Giannini S, et al. Quantitative heel ultrasound in a population-based study in Italy and its relationship with fracture history: the ESOPO study. Osteoporos Int 2006 Feb; 17 (2): 237-44
2. Díaz Curiel M, García JJ, Carrasco JL, et al. Prevalence of osteoporosis assessed by densitometry in the Spanish female population. Med Clin 2001 Jan; 116 (3): 86-8
3. Grupo de Trabajo de la Sociedad Española de Investigación Ósea y Metabolismo Mineral (SEIOMM): osteoporosis postmenopáusica. Guía de práctica clínica. Versión resumida. REEMO 2002; 11 (2): 67-78
4. Kamel HK. Underutilization of calcium and vitamin D supplements in an academic long-term care facility. J Am Med Dir Assoc 2004; 5 (2): 98-100
5. Ness J, Aronow WS, Newkirk E, et al. Underutilization of calcium and vitamin D by older adults in a large general internal medicine practice. Am J Ther 2005; 12 (2): 113-6
6. Nguyen TV, Center JR, Eisman JA. Osteoporosis: underrated, underdiagnosed and undertreated. Med J Aust 2004; 180: S18-22
7. Petrella RJ, Jones TJ. Do patients receive recommended treatment of osteoporosis following hip fracture in primary care? BMC Fam Pract 2006; 7: 31
8. Iba K, Takada J, Hatakeyama N, et al. Underutilization of antiosteoporotic drugs by orthopedic surgeons for prevention of a secondary osteoporotic fracture. J Orthop Sci 2006; 11 (5): 446-9
9. Morales A. Avances en el tratamiento de la osteoporosis al comienzo del nuevo milenio. Rev Clin Esp 2002; 202 (1): 23-6
10. Di Daniele N, Carbonelli MG, Candeloro N, et al. Effect of supplementation of calcium and vitamin D on bone mineral density and bone mineral content in peri- and post-menopause women: a double-blind, randomized, controlled trial. Pharmacol Res 2004 Dec; 50 (6): 637-41
11. McClung MR, Wasnich RD, Hosking DJ, et al. Prevention of postmenopausal bone loss: six-year results from the Early Postmenopausal Intervention Cohort Study. J Clin Endocrinol Metab 2004 Oct; 89 (10): 4879-85
12. Castelo-Branco C, Pons F, Vicente JJ, et al. Preventing postmenopausal bone loss with ossein-hydroxyapatite compounds: results of a two-year, prospective trial. J Reprod Med 1999 Jul; 44 (7): 601-5
13. Castelo-Branco C, Martínez de Osaba MJ, Pons F, et al. Ossein-hydroxyapatite compounds for preventing postmenopausal bone loss. Coadjuvant use with hormone replacement therapy. J Reprod Med 1999 Mar; 44 (3): 241-6
14. Pines A, Raafat H, Lynn AH, et al. Clinical trial of microcrystalline hydroxyapatite compound in the prevention of osteoporosis due to corticosteroid therapy. Curr Med Res Opin 1984; 8 (10): 734-42
15. Stellon A, Davies A, Webb A, et al. Microcrystalline hydroxyapatite compound in prevention of bone loss in corticosteroid-treated patients with chronic active hepatitis. Post Grad Med J 1985 Sep; 61 (719): 791-6
16. Annefeld M, Caviezel R, Schacht E, et al. The influence of ossein-hydroxyapatite compound on the healing of a bone defect. Cur Med Res Opin 1986; 10 (4): 241-50
17. Schmidt KH, Wörner VM, Buck HJ. Examination of new bone growth on aluminium oxide implant contact surfaces after oral administration of ossein-hydroxyapatite compound to rats. Curr Med Res Opin 1988; 11 (2): 107-15
18. Chavassieux P, Pastoreau P, Boivin G, et al. Effects of ossein-hydroxyapatite compound on ewe bone remodeling: biochemical and histomorphometric study. Clin Rheumatol 1991 Sep; 10 (3): 269-73
19. Saadeh PB, Mehrara BJ, Steinbrech DS, et al. Transforming growth factor-beta1 modulates the expression of vascular endothelial growth factor by osteoblasts. Am J Physiol 1999; 277: 628-37
20. Rosen CJ, Donahue LR, Hunter SJ. Insulin-like growth factors and bone: the osteoporosis connection. Proc Soc Exp Biol Med 1994 Jun; 206 (2): 83-102
21. Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. Bull World Health Organ 2003; 81 (9): 646-56
22. Ciria M, Laiz A, Benito P. Osteoporosis y grado de conocimiento de la misma en la población española. In: Sociedad Española de Reumatología y MSD. Estudio EPISER. Prevalencia e impacto de las enfermedades reumáticas en la población adulta española 2001: 101-24
23. Expert committees and study groups. Prevention and management of osteoporosis. Geneva Report of a WHO Scientific Group; 2000 Apr [online]. Available from URL: http:// www.who.int/gb/ebwha/pdf_files/EB114/B114_13-en.pdf [Accessed 2006 Feb 7]
24. Rüegsegger P, Keller A, Dambacher MA. Comparison of the treatment effects of ossein-hydroxyapatite compound in osteoporotic females. Osteoporos Int 1995 Jan; 5 (1): 30-4
25. Grupo osteoporosis de la SemFYC. Osteoporosis. Guía de abordaje. Recomendaciones SemFYC. Barcelona: EDIDE, 2000